Migraine drug rimegepant's pregnancy safety under review
NCT ID NCT05198245
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether the migraine medication rimegepant is safe to take during pregnancy. Researchers will compare pregnancy outcomes in women who took rimegepant to those who did not. The study includes women aged 16 to 49 with migraine. However, only one person has been enrolled so far, so results are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rimegepant
- What this could lead to
- If successful, this study could provide important safety information about using rimegepant during pregnancy, helping doctors and patients make informed decisions.
- What could go wrong
- This is a small, retrospective study with only one enrolled participant, so results may not be reliable or generalizable to all pregnant women with migraine.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a numbing nose treatment stop migraine pain in its tracks?
- Can migraine meds be safe while breastfeeding? a new study investigates
- Could a symptom registry unmask hidden migraine variants?
- A migraine-blocking antibody tested in children as young as 6
- Mind over migraine: brain network may explain why some expect side effects
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?